Abstract
Background The Canadian government has legalized and regulated access to cannabis as of October 2018. In this context, there is a need to analyze data that may provide insights on the effects of increased accessibility and tolerance for cannabis use. One source of data is the phenomenon known as “4/20”, a decades-old yearly mass gathering event supporting the legalization of cannabis. These events offer naturalistic epidemiologic data to ascertain specific impacts of cannabis consumption in a context of increased tolerance on health service utilization. Our study assessed the association between cannabis mass gathering events and health service utilization related to mental illness and substance use disorders at the nearest local emergency department.
Methods Emergency department service utilization data (2005-2015) was used. The sample analyzed consists of emergency department visits due to mental and substance use disorders. A multiple linear regression model was used to predict the number of daily visits with year, month, day of the week, and day of income assistance distribution as independent variables. Daily residuals were averaged, and residuals for the days with the highest number of visits were compared with the mean residual number of visits. Also, correlation of number of visits with attendance to mass gathering events was explored.
Results The residual number of visits for mental health and substance use disorder was the highest on April 20th 2015 (n=51.0, z-score=11.0, p<0.001), and on days associated with subsequent cannabis mass gathering events. Moreover, this number of visits is positively correlated with the number of attendees at the “4/20” event (Pearson’s correlation coefficient: 0.76, 95% CI: 0.19 to 0.956, p=0.002), and increased over time.
Conclusion Cannabis mass gathering events were associated with an increased number of emergency visits for patients with mental health and substance use diagnoses at the nearest local emergency department. In the context of legalization and regulation of cannabis use, these specific gatherings will not necessarily be discontinued. Indeed, as per news reports the recent post-legalization “4/20” drew tens of thousands of people in Vancouver. Also, in the new context other non-specific mass gatherings may also lead to foreseeable episodic surges in ER utilization. In light of this and from a public health perspective, services need to be prepared to care for predictably larger numbers of people suffering cannabis intoxication during mass gatherings, as well as to make provisions to provide all other services that are regularly needed for other emergency conditions. Also, educational campaigns about responsible use during these events will become particularly important, as well as offering on-site support, triage and basic services. This will allow for specific care to be provided in a non-stigmatizing manner, proportional to need, and without overcrowding general emergency services.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests: Dr. Lombardo reports grants from the Swiss National Science Foundation (P2LAP3_164907). Dr. Vila-Rodriguez reports research grants from CIHR, Brain Canada, Michael Smith Foundation for Health Research, and Vancouver Coastal Health Research Institute; reports receiving in-kind equipment support for this investigator-initiated trial from MagVenture; and has been on an advisory board for Janssen. The remainder authors declare that they have no competing interests.
Funding: There was no funding source for this study.
Data Availability
Due to privacy laws data is not available